Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease

Fig. 2

Future perspective: Today every patient receives adjuvant chemotherapy after surgical resection, regardless of individual tumor characteristics (a). If it is possible to predict the pattern of failure reliably, tumor treatment can be individualized and linked to biomarker expression patterns. Patients most likely developing metastatic spread might need intensified chemotherapy. Patients developing local recurrence might benefit from localized therapies like radiochemotherapy (b)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us